Variable | Non-survivors (n = 16) | Survivors (n = 117) | P-value |
---|---|---|---|
Basic | |||
HbA1c, % | 6.7 (6.2–8.5) | 6.4 (6.1–7.1) | 0.25 |
Fasting glucose, mmol/l | 5.0 (4.2–6.5) | 6.0 (5.3–7.4) | 0.06 |
Creatinine, µmol/l | 82.0 (77.0–113.5) | 81.0 (65.0–96.0) | 0.17 |
Total cholesterol, mmol/l | 3.4 (3.3–4.4) | 4.3 (3.6–5.0) | 0.03 |
LDL-cholesterol, mmol/l | 1.7 (1.4–2.4) | 2.4 (1.9–3.0) | 0.01 |
HDL-cholesterol, mmol/l | 1.2 (1.0–1.5) | 1.3 (1.1–1.6) | 0.30 |
Triglycerides, mmol/l | 1.0 (0.9–1.6) | 1.3 (1.0–1.8) | 0.22 |
High-sensitivity C-reactive protein, mg/l | 3.3 (1.9–6.0) | 1.9 (1.0–3.4) | 0.04 |
Coagulation parameters | |||
Fibrinogen, g/l | 3.2 (2.8–3.5) | 3.0 (2.6–3.5) | 0.32 |
Peak thrombin, nM | 253.5 (212.0–289.5) | 228.0 (201.0–268.0) | 0.17 |
Plasminogen activity, % | 105.5 (88.5–115.5) | 105.0 (98.0–117.0) | 0.48 |
tPA antigen, ng/ml | 11.8 (9.3–15.6) | 11.2 (10.0–13.2) | 0.49 |
PAI-1 antigen, ng/ml | 32.1 (29.5–37.1) | 32.1 (29.5–37.1) | 0.88 |
α2-antiplasmin activity, % | 115.0 (101.0–121.0) | 115.0 (101.0–121.0) | 0.16 |
TAFI activity, % | 97.5 (89.0–106.0) | 97.5 (89.0–106.0) | 0.72 |
Thrombomodulin antigen, ng/ml | 3.1 (2.3–3.6) | 3.01 (2.3–3.6) | 0.91 |
Fibrin clot properties | |||
Lag phase, s | 42.5 (40.0–44.5) | 43.0 (40.0–46.0) | 0.67 |
∆Abs, 405 nm | 0.825 (0.800–0.860) | 0.810 (0.770–0.850) | 0.26 |
Ks, × 10–9 cm2 | 7.0 (6.2–7.3) | 7.1 (6.6–7.7) | 0.13 |
Compaction, % | 44.0 (39.5–46.0) | 44.0 (40.0–49.0) | 0.47 |
CLT, min | 88.0 (79.0–104.5) | 95.0 (82.0–105.0) | 0.45 |
t50%, min | 10.15 (9.60–10.95) | 9.8 (9.0–10.4) | 0.06 |
D-Dmax, mg/l | 4.18 (3.77–4.48) | 3.85 (3.60–4.09) | 0.01 |
D-Drate, mg/l/min | 0.069 (0.064–0.071) | 0.070 (0.068–0.073) | 0.02 |